Discover how Celsis® ATP-bioluminescence is a viable solution for complex therapeutics
Advanced Drug Delivery Systems (ADDS) are transforming pharmaceutical manufacturing by enhancing drug efficacy, targeting, and patient compliance. By encapsulating drugs within advanced matrices like liposomes, polymeric nanoparticles, and drug-eluting stents, ADDS minimize side effects, reduce dosing frequency, and improve therapeutic outcomes.
This innovative development opens new doors in treating diseases, offering more effective and convenient treatment options for patients. However, the unique characteristics that make these formulations advantageous can also pose challenges for traditional microbial detection methods; in fact, the presence of nanomaterials, high viscosity, and interactions with microorganisms in delivery systems can complicate their sterility testing.
Membrane filtration can be impeded by formulation viscosity or particulates. These formulations further impact media with the direct inoculation method, causing it to appear cloudy and requiring a time-consuming subculture for result confirmation. These limitations underscore the necessity for alternative testing approaches that can navigate the intricacies of ADDS. Read more >
Charles River’s QC microbiology testing portfolio brings you modern products and services that deliver accurate, relevant, and reliable data to allow you to make confident decisions on your product quality and contamination control. Our unique combination of Endosafe® endotoxin testing, Celsis® rapid microbial detection, and Accugenix® microbial identification and strain typing keeps your manufacturing operations running efficiently and smoothly, lowers your cost to manufacture, and protects your reputation.
